Fatty Liver Disease

Francisca Herrera Vielma et al. (2025) · Pharmaceuticals (Basel, Switzerland)

This narrative review pulled together the existing lab and animal research on dandelion (Taraxacum officinale) — the common yellow-flowered "weed" long used in folk medicine across Europe, China, and North America for liver complaints — to ask what modern science actually shows about its ability to protect the liver. Liver disease, especially fatty liver linked to obesity and metabolic syndrome, is a fast-growing health problem with no approved drug treatment, which is part of what motivated researchers to revisit this traditional remedy scientifically. The review authors compiled dozens of published studies testing dandelion leaf, root, and whole-plant extracts, plus an isolated dandelion compound called taraxasterol, across many animal and cell models of liver injury: damage from drug overdose (acetaminophen), industrial toxins (carbon tetrachloride), alcohol, diabetes, and even liver cancer. No studies in human patients or volunteers were included anywhere in this review — every finding described here comes from lab-bench or animal-model science, not from people, which matters when weighing how confidently these results apply to human liver health. Across nearly every model tested, dandelion extracts and taraxasterol reduced liver damage markers, calmed inflammation, and boosted the body's own antioxidant defenses, with liver enzyme levels (AST, ALT) dropping toward normal after treatment. In one fatty-liver model, a leaf extract normalized blood sugar and insulin while cutting fat buildup in the liver, along with triglycerides and cholesterol. In cancer models, taraxasterol slowed tumor growth and helped cancer cells self-destruct while boosting immune activity against the tumor. The compound appears to work chiefly through two pathways: activating the cell's Nrf2 antioxidant defense system and blocking NF-κB, a master switch for inflammation. Doses used in these animal studies were often well above what a person would take in typical herbal use, so exact human relevance is unclear. These findings make a strong mechanistic case for dandelion's liver-protective potential, but the authors are clear this remains preclinical: no human clinical trials have tested it for liver disease, and animal-to-human translation is uncertain. Dandelion can interact with blood thinners, diuretics, and blood-pressure medication, and the review flags severe liver or kidney disease and pregnancy as situations where its safety has not been established. Real clinical trials are the necessary next step before dandelion can be recommended as a liver treatment.